A Study of Gefapixant (MK-7264) in Adult Participants With Chronic Cough (MK-7264-030)
Status:
Completed
Trial end date:
2020-10-30
Target enrollment:
Participant gender:
Summary
The primary objectives of this study are to evaluate the efficacy of gefapixant (MK-7264) in
reducing cough frequency as measured over a 24-hour period, and to determine the safety and
tolerability of gefapixant. The primary hypothesis is that at least one dose of gefapixant is
superior to placebo in reducing coughs per hour (over 24 hours) at Week 24.